Share on StockTwits

Analysts at Stifel Nicolaus lifted their price target on shares of Relypsa (NASDAQ:RLYP) from $45.00 to $47.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 82.88% from the company’s current price.

Shares of Relypsa (NASDAQ:RLYP) opened at 25.70 on Tuesday. Relypsa has a 52 week low of $11.55 and a 52 week high of $52.74. The stock has a 50-day moving average of $23.98 and a 200-day moving average of $28.62. The company’s market cap is $869.8 million.

Relypsa (NASDAQ:RLYP) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.57) by $0.06. Analysts expect that Relypsa will post $-2.50 EPS for the current fiscal year.

Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.